1. Introduction {#sec1}
===============

Gestational diabetes mellitus (GDM) is a type of glucose intolerance first discovered during pregnancy \[[@B1]\] and is one of the most common complications of pregnancy, resulting in hyperglycemia of variable severity. It is a severe threat to the health of both mother and child. The pathogenesis of GDM remains unclear, but the discovery of gas-signaling molecules provides a new facet for GDM research. Hydrogen sulfide (H~2~S) is the third endogenous gas-signaling molecule discovered in recent years and is produced mainly by cysteine under the action of CSE (cystathionine-*γ*-lyase) in cardiovascular tissue \[[@B2], [@B3]\]. Previous research has found that H~2~S levels were downregulated in gestational hypertension (GH) patients \[[@B4], [@B5]\]. This suggested that H~2~S plays an important role in complications of pregnancy as well, making understanding of the levels and mechanisms of H~2~S in GDM an important research topic. Here, we study the different concentrations of plasma H~2~S in patients and the related mechanism to investigate the role of H~2~S in the pathogenesis of GDM.

2. Materials and Methods {#sec2}
========================

2.1. Diagnosis of GDM {#sec2.1}
---------------------

Diagnoses of GDM were made following the recommended diagnostic criteria of the International Association of the Diabetes and Pregnancy Study Groups 2010 (IADPSG 2010). These new criteria recommend a universal 75 g oral glucose tolerance test (OGTT) screening for pregnant women at 24-28 weeks, which employs more rigorous glucose level cut-offs. The diagnostic thresholds for OGTT include a fasting blood sugar (FBS) value of 5.1 mmol/L (92 mg/dL) and one-hour and two-hour posttolerance test blood sugar values of 10.0 and 8.5 mmol/L (180 and 153 mg/dL), respectively. GDM was diagnosed if any of the blood sugar values reached or exceeded these thresholds.

2.2. Study Subjects and Groups {#sec2.2}
------------------------------

*Inclusion and exclusion criteria*: pregnant women and newborns meeting the following criteria were included in our study: single pregnancy; full-term pregnancy, primipara/second-child pregnant women without abortion or induction of labor, and no diabetes mellitus or GDM prior to the current pregnancy.

Samples for the current study were collected from 362 patients who underwent routine pregnancy check-ups and delivery in the Department of Obstetrics at the Second People\' s Hospital of Liaocheng, Shandong, China, between January 2015 and December 2018. Signed informed consent forms were obtained from all patients prior to their inclusion in this study, and our experimental protocols were approved by the ethics committee of the Second People\'s Hospital of Liaocheng. Patient charts were reviewed to obtain the venous blood of the parturient 5 days before childbirth and umbilical vein blood (UVB) and peripheral venous blood (PVB) one hour after delivery of newborns.

The patients (parturient and newborns) were divided into three groups: the control group (ctrl) was composed of normal pregnant women without complications during pregnancy, especially the 75 g OGTT at 24-28 weeks; the GDM group (GDM-) was composed of pregnant women diagnosed with GDM at 24-28 weeks and well controlled with a diet program change and/or medical treatment (such as insulin injection or MTF (metformin) oral intake); and the hyperglycemia GDM group (GDM+) included pregnant women diagnosed with GDM at 24-28 weeks and whose hyperglycemia was poorly controlled, regardless of treatment.

2.3. Sample Preparation and Preservation {#sec2.3}
----------------------------------------

Venous blood samples from parturient women and the UVB of newborns were collected from each group and placed in dry tubes treated with heparin anticoagulant. The plasma was centrifuged at 800 rpm at 4°C, separated, and preserved at -70°C.

The blood glucose levels in the one-hour PVB of newborns were measured with a fast glucose meter (OMRON, HGM-123, OMRON Corporation, Suzhou, Jiangsu, China) and recorded.

The blood glucose, insulin, bilirubin, hemoglobin, calcium, phosphorus, and magnesium of UVB were measured by electrochemical methods using an automatic biochemical instrument (Siemens, ADVIA® XPT, Siemens Healthineers, Shanghai, China).

Insulin resistance (IR) was calculated according to the equation IR = FBS × FIRI/22.5 (FIRI: fasting insulin).

It was to be noted that the patient\'s information was just provided with the patient\'s identification number as the determination of H~2~S in plasma and ELISA, so the authors involved in data measurements were completely blind to which group the blood samples belonged.

2.4. Determination of H~2~S in Plasma {#sec2.4}
-------------------------------------

Plasma H~2~S concentrations were measured using the sulfide-sensitive electrode method (PXS-270, Shanghai, China) as described by Sun et al. \[[@B6]\].

A total of 0.1 mL plasma was added to a tube containing 0.5 mL 1% zinc acetate and 2.5 mL distilled water. Into this tube, 0.5 mL of 20 mmol/L N,N-dimethyl-p-phenylenediamine dihydrochloride in 7.2 mmol/L HCl and 0.4 mL of 30 mmol/L FeCl~3~ in 1.2 mmol/L HCl were added and incubated for 20 min at room temperature (RT). The plasma protein was removed by the addition of 1 mL of 10% trichloroacetic acid to the reaction mixture and centrifugation at 3000 r/min for 15 min. The optical absorbance of the resulting solution was measured at 670 nm using a spectrometer (Shimadzu UV 2100; Shimadzu, Kyoto, Japan).

All samples were assayed in duplicate, and the concentration in the solution was calculated against a calibration curve of NaHS (3.125-250 mmol/L).

2.5. ELISA {#sec2.5}
----------

Double-antibody human TNF-*α*, IL-1*β*, IL-6, and TGF-*β*1 ELISA kits were purchased from the Beijing BLKW Biotechnology Co., Ltd. (Beijing, China). Human Adiponutrin ELISA kits (Catalog \#: EL-PRELIM) were bought from RayBiotech Life (Peachtree Corners, Georgia, USA).

All samples and standards of different concentrations were assayed according to the manufacturers\' instructions. Briefly, samples (100 *μ*L/well) were added and sealed and incubated at RT for 120 minutes. The plate was washed five times and patted dry. Biotinylated antibody working solution was added (100 *μ*L/well) and the plate sealed and incubated at RT for 60 minutes. The plate was washed again 5x and patted dry. Enzyme conjugate working fluid (100 *μ*L/well) was added and the plate sealed and incubated at RT for 20 minutes. The plate was washed and dried a final time, and the color-developing substrate solution was added (TMB 100 *μ*L/well) and incubated at RT for 20 minutes. 50 *μ*L/well stop solution was added, and the OD~450~ was measured immediately after mixing.

2.6. Statistical Analysis {#sec2.6}
-------------------------

Statistical analyses were performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA), and results were expressed as mean ± standard deviation (SD). The differences among independent samples were tested by one-way ANOVA. The relation between two groups was analyzed by linear logistic regression. We performed independent sample *t*-tests, and *p* \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. The Difference of Clinicopathological Characteristics {#sec3.1}
----------------------------------------------------------

According to our inclusion and exclusion criteria, excluding samples without complete information, 185 women and newborns in the control group, 125 cases in the GDM- group, and 52 cases in the GDM+ group were involved in our analysis.

We analyzed the age, ratio of first/second child, weight, BMI (body mass index, the weight in kilograms divided by the square of the height in meters, kg/m^2^) of parturient, and the gender and weight of newborns. As shown in our results, there were no differences in the age of expectant mothers (*p* = 0.397), and no significant differences in the ratio of parity (*p* = 0.952), height (*p* = 0.944), or weight of either pregnant women or newborns (*p* = 0.176, 0.138), or gender of offspring (*p* = 0.749) were observed. The BMI of the 3 groups also showed no differences (*p* = 0.249).

3.2. H~2~S Was Downregulated in GDM {#sec3.2}
-----------------------------------

The concentration of H~2~S from pregnant women and the UVB of newborns was measured using the sulfide-sensitive electrode method. The average concentration was downregulated in the well-controlled GDM- patients and obviously decreased in poorly controlled GDM+ patients. The average concentrations were 51.76 ± 4.98, 38.78 ± 4.57, and 25.22 ± 1.94 *μ*mol/L in the control, GDM-, and GDM+ groups, respectively, in women ([Figure 1(a)](#fig1){ref-type="fig"}, *p* \< 0.001) and 48.21 ± 4.55, 38.90 ± 5.16, and 27.29 ± 5.80 *μ*mol/L, respectively, in newborns ([Figure 1(b)](#fig1){ref-type="fig"}, *p* \< 0.001).

3.3. Hyperglycemia in Pregnancy Leads to Hypoglycemia in Newborns {#sec3.3}
-----------------------------------------------------------------

As shown in [Figure 2(a)](#fig2){ref-type="fig"}, the average blood glucose levels were no different between the control group and the GDM- group, but the GDM+ group was different from those two groups ([Figure 2(a)](#fig2){ref-type="fig"}, *p* \< 0.01 and *p* \< 0.001, respectively). The one-hour glucose of newborns showed an opposite tendency from expectant women. The average glucose showed no difference ([Figure 2(b)](#fig2){ref-type="fig"}, *p* = 0.514), but the ratio of hypoglycemia in newborns, 2/185, 10/115, and 10/42, showed great differences ([Figure 2(c)](#fig2){ref-type="fig"}, *p* \< 0.001). Compared to the concentration of blood glucose in parturient and 1-hour newborns, with the increase of blood glucose levels, the 1-hour blood glucose of newborns was reduced, and the elevated blood glucose seemed to be a leading factor of hypoglycemia ([Figure 2(d)](#fig2){ref-type="fig"}). This result shows that hyperglycemia in pregnant women leads to hypoglycemia in 1-hour newborns. Among these 3 groups, the elevated glucose in pregnancy was related to the decreased expression of H~2~S ([Figure 2(e)](#fig2){ref-type="fig"}, *p* \< 0.01). In newborns, the reduced expression of H~2~S seems to be an inducement of the ratio of hypoglycemia in newborns ([Figure 2(f)](#fig2){ref-type="fig"}).

Biochemical markers, such as incidence of physiological/pathological jaundice (97/185, 73/125, and 31/52), hemoglobin of UVB (178.26 ± 6.27, 174.56 ± 4.18, and 177.34 ± 6.19, *p* = 0.0611) was measured; the levels showed no significant differences among the 3 groups. Similar results were observed in calcium, phosphorus, and magnesium levels in UVB (data was not shown).

With the increase of hyperglycemia, the level of calculated IR was increased in GDM-/+ pregnancy ([Figure 2(f)](#fig2){ref-type="fig"}, *p* \< 0.0001).

3.4. Glucose Levels Influence Inflammatory Cytokines IL-6, TNF-*α*, and ADP in Pregnant Women and Newborns {#sec3.4}
----------------------------------------------------------------------------------------------------------

To understand better the mechanism of glucose in GDM patients, we measured TNF-*α*, IL-1*β*, IL-6, TGF-*β*1, and ADP in our study. As shown in Figures [3(a)](#fig3){ref-type="fig"}--[3(c)](#fig3){ref-type="fig"}, as the glucose concentration increased in pregnant women among the three groups, the levels of these 5 cytokines increased as well,, but only IL-6 ([Figure 3(a)](#fig3){ref-type="fig"}, *p* \< 0.0001) and TNF-*α* ([Figure 3(b)](#fig3){ref-type="fig"}, *p* \< 0.0001) showed statistically significant increases in both groups. IL-1*β* ([Figure 3(c)](#fig3){ref-type="fig"}, *p* = 0.5874), TGF-*β*1 ([Figure 3(d)](#fig3){ref-type="fig"}, *p* = 0.1247) and ADP ([Figure 3(e)](#fig3){ref-type="fig"}, *p* = 0.0738) showed no significant difference.

In newborns, the results showed that IL-6 ([Figure 4(a)](#fig4){ref-type="fig"}, *p* \< 0.0001), TNF-*α* ([Figure 4(b)](#fig4){ref-type="fig"}, *p* \< 0.01), TGF-*β*1 ([Figure 4(d)](#fig4){ref-type="fig"}, *p* \< 0.0001), and ADP ([Figure 4(e)](#fig4){ref-type="fig"}, *p* \< 0.001) displayed significant differences between the groups, but IL-1*β* ([Figure 4(d)](#fig4){ref-type="fig"}, *p* = 0.4125) resulted in no significant changes.

3.5. H~2~S Concentration Influences Glucose and IL-6 Levels in GDM Patients {#sec3.5}
---------------------------------------------------------------------------

In order to elucidate the function of H~2~S in GDM patients, both with well-controlled and poorly controlled blood glucose levels, we performed regression analysis on the relationship between H~2~S, IL-6, and blood glucose. As shown in [Figure 5](#fig5){ref-type="fig"}, the level of IL-6 and glucose showed a positive correlation ([Figure 5(a)](#fig5){ref-type="fig"}, *r*^2^ = 0.4358, *p* \< 0.01), but the concentration of H~2~S was negatively correlated with levels of IL-6 and glucose ([Figure 5(c)](#fig5){ref-type="fig"}, *r*^2^ = 0.521, *p* \< 0.001, and [Figure 5(e)](#fig5){ref-type="fig"}, *r*^2^ = 0.706, *p* \< 0.001).

In newborn UVB samples, the correlation of H~2~S with IL-6 and blood glucose followed the same pattern as in GDM patients. IL-6 and glucose were positively correlated ([Figure 5(b)](#fig5){ref-type="fig"}, *r*^2^ = 0.5342, *p* = 0.02), but H~2~S was negatively correlated with IL-6 and glucose ([Figure 5(d)](#fig5){ref-type="fig"}, *r*^2^ = 0.509, *p* \< 0.001, and [Figure 5(f)](#fig5){ref-type="fig"}, *r*^2^ = 0.1217, *p* \< 0.001).

3.6. H~2~S Concentration Influences the Levels of TNF-*α* in GDM Patients {#sec3.6}
-------------------------------------------------------------------------

As with IL-6, we analyzed the relationship of H~2~S with TNF-*α* and blood glucose. As shown in [Figure 6](#fig6){ref-type="fig"}, the concentration of H~2~S was negatively correlated with levels of TNF-*α* in pregnant women and newborns ([Figure 6(a)](#fig6){ref-type="fig"}, *r*^2^ = 0.3912, *p* \< 0.001, and [Figure 6(b)](#fig6){ref-type="fig"}, *r*^2^ = 0.5278, *p* \< 0.001). The levels of TNF-*α* and glucose were positively correlated in pregnant women ([Figure 6(c)](#fig6){ref-type="fig"}, *r*^2^ = 0.3312, *p* \< 0.001) but showed no significance in newborns ([Figure 6(d)](#fig6){ref-type="fig"}, *r*^2^ = 0.0008, *p* = 0.2362).

3.7. H~2~S Concentration Influences the Levels of TGF-*β*1 and ADP in GDM Patients {#sec3.7}
----------------------------------------------------------------------------------

We analyzed the relationship of H~2~S with ADP and blood glucose. As shown in [](#supplementary-material-1){ref-type="supplementary-material"}, the concentration of H~2~S was negatively correlated with levels of TGF-*β*1 and ADP in pregnant women and newborns ([](#supplementary-material-1){ref-type="supplementary-material"}, *r*^2^ = 0.1613 and 0.1692, *p* \< 0.0001 and [](#supplementary-material-1){ref-type="supplementary-material"}, *r*^2^ = 0.4482 and 0.5245, *p* \< 0.001).

The levels of TGF-*β*1 and glucose were positively correlated in pregnant women ([](#supplementary-material-1){ref-type="supplementary-material"}, *p* \< 0.0001) but showed no significance in newborns ([](#supplementary-material-1){ref-type="supplementary-material"}, *p* = 0.6876); as per analysis shown in Figures [3(d)](#fig3){ref-type="fig"} and [4(d)](#fig4){ref-type="fig"}, the results showed no significance.

The levels of ADP and glucose showed the same results, and they were positively correlated in pregnant women ([](#supplementary-material-1){ref-type="supplementary-material"}, *p* \< 0.0001) but showed no significance in newborns ([](#supplementary-material-1){ref-type="supplementary-material"}, *p* = 0.1249); as per analysis shown in Figures [3(e)](#fig3){ref-type="fig"} and [4(e)](#fig4){ref-type="fig"}, the results showed no significance.

4. Discussion {#sec4}
=============

GDM is one of the common perinatal complications, and its pathogenesis remains not yet fully understood. Many studies have shown that the risk of type 2 diabetes mellitus (T2DM) in pregnant women with GDM has increased significantly \[[@B7]\]. GDM is considered an early stage of T2DM. The classic view held that the antagonistic effects of prolactin, prolactin, glucocorticoid, and progesterone on insulin secretion and insulin resistance during pregnancy were the main causes of GDM. Although there exists insulin resistance in every pregnant woman, only 4% of pregnant women will eventually develop GDM, which suggests that there may be other reasons for the pathogenesis of GDM \[[@B8]\]. In addition, studies have found that the occurrence of GDM is related not only to insulin secretion and dysfunction but also to some inflammatory and fatty factors \[[@B9], [@B10]\]. However, the etiology of GDM is still not fully understood.

Recently, H~2~S has been found to have important biological functions. As an endogenous gas-signaling molecule, H~2~S has many biologically important characteristics, such as small molecular weight, continuous production, rapid diffusion, and wide effects. It is generated in cardiovascular tissues under the action of CSE with cysteine as the main substrate \[[@B2], [@B3]\]. Some studies have found that the disorder of the H~2~S/CSE system is important in the pathogenesis of many vascular injury diseases \[[@B11], [@B12]\]. It was also found that H~2~S inhibits insulin release and regulates beta-cell survival \[[@B13]\]. Therefore, H~2~S may play a role in the pathogenesis of diabetes mellitus. The purpose of this study was to investigate whether there were differences in H~2~S in the venous blood of GDM patients and normal pregnant women and the UVB of newborns and to explore the mechanism of these differences in the pathogenesis of GDM.

This study found that plasma levels of H~2~S in the venous blood and neonatal umbilical vein blood of GDM patients were significantly lower than those of normal pregnant women, suggesting that H~2~S is involved in the pathogenesis of GDM. As the average blood glucose rose among the 3 groups, the H~2~S concentrations decreased. The state of hyperglycemia in GDM patients was closely related to the decrease of H~2~S concentration.

Previous studies have found that, in high glucose-induced insulin resistance rat model animals, plasma H~2~S levels and the expression of CSE were significantly lower than those in the control group. The pathogenesis of GDM was closely related to insulin resistance, so we speculated that the pathogenesis of GDM was closely related to the downregulation of the H~2~S/CSE system. The results of this study validate this hypothesis. In the cardiovascular system and in the pancreas, CSE is a rate-limiting enzyme catalyzing H~2~S production. Therefore, in the venous blood of GDM patients, whether the decrease of H~2~S concentration is related to the decrease of CSE activity or expression remains to be studied further.

In the current study, the blood glucose levels of the GDM- group were maintained in the normal range by dietary control or insulin treatment, and hypoglycemia still occurred in newborns. The ratio of hypoglycemia in newborns of the GDM- group was significantly greater than that of the normal control group 1 hour after birth. The incidence of hypoglycemia in newborns of the GDM+ group was higher, and the average blood glucose value was lower, which suggested that hyperglycemia in GDM patients is an important risk factor for neonatal hypoglycemia.

As measured in our study, the biochemical markers bilirubin, hemoglobin, calcium, phosphorus, and magnesium showed no significant differences in the UVB among the 3 groups. For GDM newborns, however, they are important risk factors to monitor to ensure the health and safety of newborns.

Many inflammatory factors, such as TNF-*α* and IL-6, have strong biological activities and act in the inflammatory response of many diseases. IL-6 has been proven to be involved in many inflammatory reactions and has the ability to regulate the balance of energy metabolism \[[@B14]\]. It has been reported that the serum levels of IL-6 and hs-CRP (high-sensitivity C-reactive protein) in patients with GDM are significantly increased \[[@B10]\], but the mechanism is not fully understood, and the causal relationship with insulin resistance is still controversial. It has been reported that the initiating factor of insulin resistance may be chronic inflammation, and it has been speculated that IL-6 may be involved in the occurrence of GDM \[[@B15], [@B16]\].

Some studies suggest that TNF-*α* and IL-6 interact to interfere with insulin signal transduction, which leads to insulin resistance and eventually to the occurrence of GDM \[[@B17], [@B18]\]. IL-6 may be involved in the immune response to inflammation and play a bridge role between local tissue damage and systemic immune response. At the same time, it also promotes cell apoptosis and worsens GDM \[[@B19], [@B20]\]. TNF-*α* is mainly distributed on the surface of vascular endothelial cells, which can directly affect islet cells and lead to insulin resistance. Our results showed that the levels of TNF-*α* and IL-6 in the GDM group were significantly higher than those in the control group (*p* \< 0.0001). Our study showed that IL-6, TNF-*α*, and IR had a certain correlation, suggesting that TNF-*α* and IL-6 could be used as important indicators for the detection and diagnosis of gestational diabetes mellitus.

ADP is secreted mainly by adipocytes and has 244 amino acids. It has the functions of regulating glycolipid metabolism, acts as an anti-inflammatory, and reduces insulin resistance. Some studies have shown that when GDM occurs, ADP levels decrease significantly and are prefatory to the occurrence of abnormal blood sugar \[[@B21]\]. This study found that the ADP level of the GDM group was significantly lower than that of the control group in newborns, but there were no significant differences in pregnant women with GDM.

Differential expression of TGF-*β*1 seemed to be related with other factors in newborns, but its levels did not differ in the control and GDM-/+ groups of parturient women.

5. Conclusions {#sec5}
==============

This study confirms that the downregulation of H~2~S participates in the pathogenesis of GDM and is of great significance in understanding the differences in H~2~S in GDM and normal pregnant women and newborns. The cause of the H~2~S concentration decrease in GDM, how H~2~S participates in the pathogenesis of GDM, and which part of the pathogenesis of GDM is affected by H~2~S are all issues that urgently need to be resolved. Furthermore, the current study suggests that IL-6 and TNF-*α* are correlated with gestational diabetes mellitus, but further study is necessary to explain whether they have causal relationship. In summary, this study expands the research field of H~2~S and provides new insights for exploring further the pathogenesis of GDM.
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###### 

Figure S1: H~2~S concentration did not influence the level of TGF-*β*1 in GDM patients. (A, B) The concentration of H~2~S was negatively correlated with levels of TGF-*β*1 and ADP in pregnant women and newborns. (1C, D) The levels of TGF-*β*1 and glucose were positively correlated in pregnant women but showed no significance in newborns. Figure S2: H~2~S concentration did not influence the level of ADP in GDM patients. (A, B) The concentration of H~2~S was negatively correlated with levels of ADP and ADP in pregnant women and newborns. (C, D) The levels of ADP and glucose were positively correlated in pregnant women but showed no significance in newborns.

###### 

Click here for additional data file.

![Concentration of H~2~S detected in the venous blood of parturient women and the UVB of newborns. (a) Concentration of H~2~S detected in the venous blood of pregnant women was decreased among the control, GDM-, and GDM+ groups. (b) Concentration of H~2~S detected in the UVB of newborns was decreased among the control, GDM-, and GDM+ groups.](JDR2020-3085840.001){#fig1}

![Blood glucose level and its relation with H~2~S concentration and hypoglycemia in newborns. (a) Blood glucose was elevated among pregnant women in the control, GDM-, and GDM+ groups. (b) The 1-hour blood glucose in newborns showed no differences among the control, GDM-, and GDM+ groups. (c) The ratio of hypoglycemia in newborns, 2/185, 10/115, and 10/42, showed great differences. (d) Comparison of blood glucose concentrations in pregnant women and 1-hour-old newborns. With the increase of blood glucose level, the 1-hour blood glucose of newborns was downregulated, and elevated blood glucose seems to be a leading factor for hypoglycemia. (e) Among these 3 groups, the elevated glucose in pregnant women was related to the decreased expression of H~2~S. (f) In newborns, the decreased H~2~S concentration seems an inducement of the ratio of hypoglycemia in newborns. (g) With the increase of hyperglycemia, the level of IR was upregulated in GDM-/+ pregnant women.](JDR2020-3085840.002){#fig2}

![The level of glucose influenced the inflammatory cytokines TNF-*α*, IL-1*β*, IL-6, TGF-*β*1, and ADP in pregnant women. (a, b) The expression of IL-6/TNF-*α* was increased among the control, GDM-, and GDM+ groups in pregnant women. (c--e) The expression of IL-1*β*, TGF-*β*1, and ADP showed no differences among the control, GDM-, and GDM+ groups in pregnant women.](JDR2020-3085840.003){#fig3}

![The level of glucose influenced the inflammatory cytokines TNF-*α*, IL-1*β*, IL-6, TGF-*β*1, and ADP in newborns. (a) The expression of IL-6/TNF-*α* was increased among the control, GDM-, and GDM+ groups. (c) The expression of IL-1*β* showed no differences among the control, GDM-, and GDM+ groups. (d) The expression of TGF-*β*1 was increased among the control, GDM-, and GDM+ groups in newborns. (e) The expression of ADP was decreased among the control, GDM-, and GDM+ groups.](JDR2020-3085840.004){#fig4}

![The concentration of H~2~S influenced the glucose and IL-6 levels in GDM patients. (a) The levels of IL-6 and blood glucose were positively correlated. (c, e) The concentration of H~2~S was negatively correlated with levels of IL-6 and glucose. (b) IL-6 and glucose were positively correlated in the UVB of newborns. (d, f) H~2~S was negatively correlated with IL-6 and glucose in newborn UVB.](JDR2020-3085840.005){#fig5}

![H~2~S concentration influenced the level of TNF-*α* in GDM patients. (a, b) H~2~S concentration was negatively correlated with TNF-*α* levels in pregnant women and newborns. (c) The levels of TNF-*α* and glucose showed a positive correlation in pregnant women. (d) The levels of TNF-*α* and glucose showed no significant correlation in newborns.](JDR2020-3085840.006){#fig6}
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